Skye Bioscience, Inc.

SKYE • Biotechnology

$1.86

▲ +0.08 (+4.49%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$73.81M

Crecimiento

-100.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 3.3Rentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 11 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.86

Change4.49%

Shares Out39.68M

Market Cap$73.81M

Enterprise Value$56.76M

52W Range0.57 - 5.75

Beta2.87

P/E-1.29

P/B8.19

P/FCF-1.74

EV/EBITDA-1.00

EV/FCF-1.34

Price$1.86

Change4.49%

Shares Out39.68M

Market Cap$73.81M

Enterprise Value$56.76M

52W Range0.57 - 5.75

Beta2.87

P/E-1.29

P/B8.19

P/FCF-1.74

EV/EBITDA-1.00

EV/FCF-1.34

Earnings Yield-77.68%

FCF Yield-57.49%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio3.30

Quick Ratio3.30

Revenue 5Y-100.00%

Target$12.00

Target Upside545.16%

Target Median$15.00

Target Range2.00 - 21.00

Volume193.90K

Avg Volume200.76K

EPS Surprise-0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

91/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 3.3Rentabilidad débil

Analyst view

Analyst sentiment and price target

SKYE

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-24

Bajo

$2.00

Promedio

$12.00

Mediana

$15.00

Alto

$21.00

Resumen de la compañía

IPO: 1/6/2015

Industria: Biotechnology

P/B i: 8.19

Deuda / Patrimonio i: 0.01

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 3.30

Ratio rápido: 3.30

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Sharp John P

Transacción: 03/31/2026

OTRO

Cambio

Precio

Not reported

Presentación

04/28/2026

Tipo

OTRO

DHILLON PUNIT

Transacción: 03/31/2026

VENTA

Cambio

-21,586

Precio

$3.50

Presentación

04/02/2026

Tipo

VENTA

Diep Tuan Tu

Transacción: 03/31/2026

VENTA

Cambio

-75,000

Precio

$14.56

Presentación

04/02/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Sharp John P	OTRO	0	Not reported	03/31/2026	04/28/2026
DHILLON PUNIT	VENTA	-21,586	$3.50	03/31/2026	04/02/2026
Diep Tuan Tu	VENTA	-75,000	$14.56	03/31/2026	04/02/2026
Schwab Andrew J.	COMPRA	+75,000	$0.61	03/31/2026	04/02/2026
Grayson Paul A.	COMPRA	+75,000	$0.61	03/31/2026	04/02/2026
Charych Deborah H.	COMPRA	+75,000	$0.61	03/31/2026	04/02/2026
Jenkins Annalisa	COMPRA	+75,000	$0.61	03/31/2026	04/02/2026
Twitty Christopher	VENTA	-12,000	$4.25	03/31/2026	04/02/2026
Smith Karen L.	COMPRA	+75,000	$0.61	03/31/2026	04/02/2026
Diep Tuan Tu	OTRO	+9,194	$3.50	03/04/2024	04/02/2026
Diep Tuan Tu	OTRO	0	Not reported	03/04/2024	04/02/2026
DHILLON PUNIT	COMPRA	+280,000	$0.82	02/06/2026	02/09/2026
Arora Puneet S.	COMPRA	+125,000	$0.82	02/06/2026	02/09/2026
Diep Tuan Tu	COMPRA	+125,000	$0.82	02/06/2026	02/09/2026
Jenkins Annalisa	COMPRA	+35,000	$0.82	02/06/2026	02/09/2026
Charych Deborah H.	COMPRA	+35,000	$0.82	02/06/2026	02/09/2026
Twitty Christopher	COMPRA	+150,000	$0.82	02/06/2026	02/09/2026
ARSENAULT KAITLYN	COMPRA	+125,000	$0.82	02/06/2026	02/09/2026
Smith Karen L.	COMPRA	+35,000	$0.82	02/06/2026	02/09/2026
Grayson Paul A.	COMPRA	+35,000	$0.82	02/06/2026	02/09/2026

Sobre la compañía

Skye Bioscience, Inc.

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Fuente - Link

Competidores

ALGS BRNS CVM INMB KZR LVTX MRSN PDSB XFOR XLO

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Skye Bioscience to Merge With Redx, Forming Fibrosis-Focused Fibrx Therapeutics

Skye Bioscience (NASDAQ: SKYE) and privately held Redx announced a definitive transaction agreement that would combine the companies into a Nasdaq-listed fibrosis-focused biotechnology company named Fibrx Therapeutics. The transaction, unanimously approved by both companies' boards, is expected to close in the fourth quarter of 2026, subject to shareholder approvals, customary closing conditions, approval of the Redx

Defense World

Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript

Seeking Alpha

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company's lead program will be RXC008, Redx's GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, with an open U.S. IND, FDA Fast Track designation, and a planned Phase 2 clinical study Concurrent aggregate financings of approximately $125 million committed by a syndicate of new and existing leading healthcare institutional investors Financings expected to fund operations through RXC008 Phase 2 clinical trial – topline data expected H2 2028 Companies to hold a joint conference call on August 14, 2026 at 10 a.m. ET SAN DIEGO and ALDERLEY PARK, United Kingdom, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (“Skye”) (Nasdaq: SKYE), and Redx Pharma Limited (“Redx”), a U.K. based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, today announced that they have entered into a definitive transaction agreement (the “Transaction Agreement”).

GlobeNewsWire

Skye Bioscience (NASDAQ:SKYE) Trading 2.8% Higher – Time to Buy?

Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report)'s share price was up 2.8% during mid-day trading on Monday. The stock traded as high as $0.5918 and last traded at $0.5842. Approximately 102,145 shares were traded during trading, a decline of 16% from the average session volume of 122,073 shares. The stock had previously closed

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-11	-0.29	-0.32	-0.03
2026-03-10	-0.2971	-0.36	-0.0629
2025-11-10	-0.33	-0.32	0.01
2025-08-07	-0.34	-0.44	-0.1
2025-05-08	-0.31	-0.28	0.03
2025-03-20	-0.28	-0.24	0.04
2024-11-07	-0.26	-0.22	0.04
2024-08-09	-0.2	-0.2	0
2024-05-10	-0.16	-0.18	-0.02
2024-03-22	-0.38	-0.63	-0.25
2016-05-13	-0.07	-0.06	0.01